Browse by Series:

Adjuvant Therapy for Early-Stage HER2+ Breast Cancer

FACP, University of Pittsburgh School of Medicine; Hope S. Rugo, MD, UCSF Helen Diller Family Comprehensive Cancer Center; Lee Schwartzberg, MD, FACP, West Cancer Center SAMPLE Panelists:KOL NAME, institution; Breast Cancer Broadcast/News
Published: Thursday, Feb 01, 2018



With the advent of recent data, there is a focus on incorporating them into the treatment planning of HER2-positive early breast cancer. Adam M. Brufsky, MD, PhD, FACP, leads panel of experts, Kimberly Blackwell, MD; Hope S. Rugo, MD; and Lee Schwartzberg, MD, FACP, on addressing some of the questions surrounding adjuvant treatment of HER2-positive early breast cancer and how they interpret the available data.
 
Slider Left
Slider Right


With the advent of recent data, there is a focus on incorporating them into the treatment planning of HER2-positive early breast cancer. Adam M. Brufsky, MD, PhD, FACP, leads panel of experts, Kimberly Blackwell, MD; Hope S. Rugo, MD; and Lee Schwartzberg, MD, FACP, on addressing some of the questions surrounding adjuvant treatment of HER2-positive early breast cancer and how they interpret the available data.
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x